Keyphrases
Bevacizumab
53%
Glioblastoma multiforme
37%
Irinotecan
34%
Glioblastoma
30%
Human Glioblastoma
25%
Orthotopic Model
25%
Combination Therapy
19%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
19%
MicroPET
18%
Treatment Response
17%
Quality of Life
16%
Xenograft
15%
Overall Survival
15%
Prognostic Factors
15%
Bevacizumab Treatment
15%
Medicine and Dentistry
Glioblastoma
87%
Fluorine-18
29%
Neoplasm
29%
Vasculotropin
27%
Bevacizumab
21%
Irinotecan
21%
Xenograft
20%
Treatment Response
18%
Polyethylene Terephthalate
15%
Epidermal Growth Factor Receptor
15%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Bevacizumab
46%
Vasculotropin
27%
Neoplasm
24%
Irinotecan
21%
Overall Survival
18%
Fluorine 18
17%
Biological Marker
16%
Epidermal Growth Factor Receptor
15%